Back to Search Start Over

64 - Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs.

Authors :
Colclough, N.
Ballard, P.G.
Barton, P.
Chen, K.
Cross, D.A.E.
Finlay, M.R.V.
Han, L.
Janefeldt, A.
Johnström, P.
Ward, R.A.
Wrigley, G.L.
Yan, Y.
Yates, J.W.T.
Zhang, D.
Zhang, Z.
Source :
European Journal of Cancer. Dec2016 Supplement 1, Vol. 69, pS28-S28. 1p.
Publication Year :
2016

Details

Language :
English
ISSN :
09598049
Volume :
69
Database :
Academic Search Index
Journal :
European Journal of Cancer
Publication Type :
Academic Journal
Accession number :
120141027
Full Text :
https://doi.org/10.1016/S0959-8049(16)32664-8